Emcure currently has six biosimilars in the market, launched through its subsidiary Gennova Biopharmaceuticals. While it has developed these in-house so far, the drugmaker will also scout for partners with products not in their pipeline, for commercialisation… For the full story, visit the source.
Business
Emcure doubling down on biosimilars pipeline: MD Satish Mehta
Emcure currently has six biosimilars in the market, launched through its subsidiary Gennova Biopharmaceuticals. While it has developed these in-house so far, the drugmaker will also scout for partners with products not in their pipeline, for commercialisation…
By Jessica Jani· Livemint· 5 months ago· 2 min read
This summary is sourced from Livemint. Read the full article at:Livemint